4142:TPE
Adimmune Corp
NT$ 16,80
arrow_upward
+0,60%(+0,100) 1D
13 de nov., 13:30:11 GMT+8 · TWD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 4142…
Abrir
NT$ 16,85
Alta
NT$ 17,15
Baixa
NT$ 16,75
Valor de mercado
7,22 bi
Volume médio
1,13 mi
Volume
724,64 mil
Alto — 52 sem
NT$ 22,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Abrir
NT$ 16,85
Alta
NT$ 17,15
Baixa
NT$ 16,75
Valor de mercado
7,22 bi
Volume médio
1,13 mi
Volume
724,64 mil
Alto — 52 sem
NT$ 22,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Notícias
De fontes da web e parceiros de notícias
TradingKey
·
há 18 horas
Previsão para o S&P 500: Índice se Prepara para Retestar Máxima Histórica em Novembro Após Recuo de 500 Pontos, Maior Alta Diária em Quase Sete Meses
Vietnam.vn
·
há 1 dia
O S&P 500 e o Nasdaq encerraram suas sequências de quatro semanas de perdas.
Yahoo Finance
·
há 1 hora
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
BigGo Finance
·
há 7 horas
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Perfil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Sobre Adimmune Corp